Aerie pharmaceuticals announces successful interim 90-day topline data from its six-month mercury 3 clinical trial in europe

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced successful interim 90-day topline data from its six-month phase 3b clinical trial in europe known as mercury 3, comparing roclanda® to ganfort®. roclanda® is marketed in the united s
AERI Ratings Summary
AERI Quant Ranking